Skip to main content

Advertisement

Table 3 Target volume coverage and homogeneity indices for selected challenging cases

From: Helical tomotherapy in the treatment of pediatric malignancies: a preliminary report of feasibility and acute toxicity

Tumor site Histology (number of cases) Target volume Prescribed dose, Gy Mean PTV dose, Gy* Coverage Index§ Homogeneity Index§ Irradiation time (sec) †
CNS (craniospinal irradiation) Medulloblastoma (16) Whole brain 23,4 23,98 ± 0,17 0,78 (0,53-0,95) 1,10 (1,07-1,21) 912,7 (367,4 - 1991,2)
    36,0 36,96 ± 0,15 0,74 (0,47-0,90) 1,10 (1,08-1,12)  
   Cribriform plate 23,4 23,88 ± 0,07 0,86 (0,75-0,95) 1,07 (1,04-1,09)  
    36,0 36,86 ± 0,30 0,79 (0,62-1,00) 1,07 (1,06-1,09)  
   Spinal canal 23,4 23,90 ± 0,16 0,87 (0,73-0,91) 1,07 (1,06-1,09)  
    36,0 36,82 ± 0,45 0,90 (0,78-1,00) 1,07 (1,06-1,13)  
   Tumor bed 54,0 55,06 ± 0,49 0,81 (0,57-0,98) 1,05 (1,02-1,13)  
CNS Glioma (7) Tumor/tumor bed 45,0-59,4 45,18-60,76 0,89 (0,81-0,98) 1,04 (1,02-1,06) 328,0 (211,8 - 957,0)
Abdomen Neuroblastoma (7) Tumor bed 21,0 21,34 ± 0,13 0,85 (0,48-0,94) 1,07 (1,03-1,08) 256,8 (158,8 - 293,2)
Thorax Rhabdomyosarcoma (1) Right pleura 50,4 50,11 ± 0,98 0,84 1,02 730,3
  PNET (Askin's tumor) (1) Hemithorax 14,40 14,83 ± 0,19 0,89 1,09 554,1
   GTV 48,60 49,87 ± 0,79 0,74 1,06  
  Ewing sarcoma (1) Hemithorax 14,00 14,38 ± 0,24 0,77 1,07 519,0
   Tumor 48,00 49,29 ± 0,22 0,90 1,08  
   Met L2-S1 48,00 49,22 ± 0,15 0,92 1,05  
Pelvis Rhabdomyosarcoma (1) Inguinal nodes 41,40 41,94 ± 0,59 0,91 1,05 327,2
   Tumor bed 50,40 51,10 ± 0,62 0,65 1,04  
Total lymphatic irradiation Hodgkin lymphoma (1) Liver, spleen, total lymphatic 12,00 12,46 ± 0,25 0,76 1,07 538,2
   Total lymphatic 21,00 21,74 ± 0,22 0,74 1,09  
Orbit PNET (1) Tumor 48,60 49,40 ± 0,86 0,55 1,05 344,1
  Rhabdomyosarcoma (1) Tumor bed 50,40 51,93 ± 0,83 0,94 1,07 479,8
  Melanoma (1) Tumor bed 50,40 51,16 ± 0,42 0,98 1,08 329,6
  1. * Data are presented as mean ± SD or as a range of mean PTV dose
  2. § Data are presented as median (range) for groups and as single values for individual cases
  3. † Data are presented as irradiation time for the phase of treatment with longest irradiation time and as median (range) for groups